Robert Befidi
Known title: President, DiagnosticsCIK: 0002012361
Associated companies
Transaction History
| NVST | ▼ Sell | Tax Withholding | 5,147 | $141K | 8/25/2026 | View on chart |
| NVST | ▼ Sell | Tax Withholding | 2,177 | $64K | 2/25/2026 | View on chart |
| NVST | ▲ Buy | Grant | 7,605 | $0 | 2/25/2026 | View on chart |
| NVST | ▼ Sell | Tax Withholding | 3,454 | $73K | 8/25/2025 | View on chart |
| NVST | ▼ Sell | Tax Withholding | 1,123 | $23K | 2/25/2025 | View on chart |
| NVST | ▲ Buy | Grant | 10,290 | $0 | 2/25/2025 | View on chart |
| NVST | ▼ Sell | Tax Withholding | 3,454 | $65K | 8/25/2024 | View on chart |
| NVST | ▲ Buy | Grant | 9,385 | $0 | 2/25/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Piper Sandler cuts Envista price target to $26, maintains Neutral
Piper Sandler recently lowered its price target for Envista Holdings to $26 while keeping a Neutral stance. This move aligns with the stock's current trading level near its 52-week low of $18.77. The company has also scheduled its third-quarter 2026 earnings call, which will provide updated financial insights.
Piper Sandler cuts Envista price target to $26, maintains Neutral. Piper Sandler recently lowered its price target for Envista Holdings to $26 while keeping a Neutral stance. This move aligns with the stock's current trading level near its 52-week low of $18.77. The company has also scheduled its third-quarter 2026 earnings call, which will provide updated financial insights.